SHAREHOLDER ALERT: ICPT BIIB KNDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Back to Newsroom
Mentioned in this Article

SHAREHOLDER ALERT: ICPT BIIB KNDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Monday, December 28, 2020 10:20 AM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / December 28, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11809&wire=1
Lead Plaintiff Deadline: January 4, 2021
Class Period: September 28, 2019 - October 7, 2020

Allegations against ICPT include that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Biogen Inc. (NASDAQ:BIIB)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/biogen-inc-loss-submission-form?prid=11809&wire=1
Lead Plaintiff Deadline: January 12, 2021
Class Period: October 22, 2019 - November 6, 2019

Allegations against BIIB include that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Kandi Technologies Group, Inc. (NASDAQ:KNDI)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/kandi-technologies-group-inc-loss-submission-form?prid=11809&wire=1
Lead Plaintiff Deadline: February 9, 2021
Class Period: March 15, 2019 - November 27, 2020

Allegations against KNDI include that: (i) Kandi artificially inflated its reported revenues through undisclosed related party transactions, or otherwise had relationships with key customers that indicated those customers did not have an arms length relationship with Kandi; (ii) the majority of Kandi's sales in the past year had been to undisclosed related parties and/or parties with such a close relationship and history with Kandi that it cast doubt on the arms-length nature of their relationship; (iii) all the foregoing, once revealed, was foreseeably likely to cast doubt on the validity of Kandi's reported revenues and, in turn, have a foreseeable negative impact on the Company's reputation and valuation; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

The Law Offices of Vincent Wong
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: